DGX Quote, Financials, Valuation and Earnings

Danaher has a net margin of 9.08% compared to Quest Diagnostics's net margin of 14.11%. Quest Diagnostics's return on equity of 12.68% beat Danaher's return on equity of 7.47%.

Quest Diagnostics has a consensus price target of $169.96, signalling upside risk potential of 11.07%. On the other hand Danaher has an analysts' consensus of $287.70 which suggests that it could grow by 24.39%. Given that Danaher has higher upside potential than Quest Diagnostics, analysts believe Danaher is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.893, which suggesting that the stock is 10.74% less volatile than S&P 500. In comparison Danaher has a beta of 0.832, suggesting its less volatile than the S&P 500 by 16.801%.

Quest Diagnostics has a quarterly dividend of $0.75 per share corresponding to a yield of 1.93%. Danaher offers a yield of 0.45% to investors and pays a quarterly dividend of $0.27 per share. Quest Diagnostics pays 36.77% of its earnings as a dividend. Danaher pays out 26.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.5B, which are smaller than Danaher quarterly revenues of $5.8B. Quest Diagnostics's net income of $226M is lower than Danaher's net income of $818M. Notably, Quest Diagnostics's price-to-earnings ratio is 20.57x while Danaher's PE ratio is 44.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.80x versus 7.22x for Danaher. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of 9.08% compared to Quest Diagnostics's net margin of -5.4%. Quest Diagnostics's return on equity of 12.68% beat Exact Sciences's return on equity of -6.77%.

Quest Diagnostics has a consensus price target of $169.96, signalling upside risk potential of 11.07%. On the other hand Exact Sciences has an analysts' consensus of $71.86 which suggests that it could grow by 25.01%. Given that Exact Sciences has higher upside potential than Quest Diagnostics, analysts believe Exact Sciences is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.893, which suggesting that the stock is 10.74% less volatile than S&P 500. In comparison Exact Sciences has a beta of 1.237, suggesting its more volatile than the S&P 500 by 23.719%.

Quest Diagnostics has a quarterly dividend of $0.75 per share corresponding to a yield of 1.93%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 36.77% of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.5B, which are larger than Exact Sciences quarterly revenues of $708.7M. Quest Diagnostics's net income of $226M is higher than Exact Sciences's net income of -$38.2M. Notably, Quest Diagnostics's price-to-earnings ratio is 20.57x while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.80x versus 3.91x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of 9.08% compared to Quest Diagnostics's net margin of -56.28%. Quest Diagnostics's return on equity of 12.68% beat Guardant Health's return on equity of -651%.

Quest Diagnostics has a consensus price target of $169.96, signalling upside risk potential of 11.07%. On the other hand Guardant Health has an analysts' consensus of $42.30 which suggests that it could grow by 37.71%. Given that Guardant Health has higher upside potential than Quest Diagnostics, analysts believe Guardant Health is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.893, which suggesting that the stock is 10.74% less volatile than S&P 500. In comparison Guardant Health has a beta of 1.255, suggesting its more volatile than the S&P 500 by 25.526%.

Quest Diagnostics has a quarterly dividend of $0.75 per share corresponding to a yield of 1.93%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 36.77% of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.5B, which are larger than Guardant Health quarterly revenues of $191.5M. Quest Diagnostics's net income of $226M is higher than Guardant Health's net income of -$107.8M. Notably, Quest Diagnostics's price-to-earnings ratio is 20.57x while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.80x versus 5.50x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

RadNet has a net margin of 9.08% compared to Quest Diagnostics's net margin of 0.7%. Quest Diagnostics's return on equity of 12.68% beat RadNet's return on equity of -0.45%.

Quest Diagnostics has a consensus price target of $169.96, signalling upside risk potential of 11.07%. On the other hand RadNet has an analysts' consensus of $68.17 which suggests that it could grow by 23.96%. Given that RadNet has higher upside potential than Quest Diagnostics, analysts believe RadNet is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.893, which suggesting that the stock is 10.74% less volatile than S&P 500. In comparison RadNet has a beta of 1.768, suggesting its more volatile than the S&P 500 by 76.83%.

Quest Diagnostics has a quarterly dividend of $0.75 per share corresponding to a yield of 1.93%. RadNet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 36.77% of its earnings as a dividend. RadNet pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.5B, which are larger than RadNet quarterly revenues of $461.1M. Quest Diagnostics's net income of $226M is higher than RadNet's net income of $3.2M. Notably, Quest Diagnostics's price-to-earnings ratio is 20.57x while RadNet's PE ratio is 444.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.80x versus 2.94x for RadNet. Usually stocks with elevated PS ratios are considered overvalued.